Current Clinical Trials

Stress Urinary Incontinence

You may be able to take part in the study if you are:

• Are a woman at least 18 years of age,

• Still experience urine leakage on effort or exertion, or on sneezing or coughing, at least 2 times a day after surgical treatment,

• Have tried pelvic floor muscle training (PFMT) and received a surgical treatment for SUI, which didn’t resolve your symptoms.

 

​

​

​

 

​​​​​​​​​​​​Stress Urinary Incontinence

Females ages 18-55 diagnosed with stress urinary incontinence with no history of prior treatment may be eligible.

​

​

​

 

Bladder Cancer

A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Subjects with Intermediate Risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC).

The subjects must have undergone adequate Transurethral Resection of Bladder Tumor (TURBT) during screening with or without peri-operative intravesical chemotherapy within 60 days prior randomization, and must have one of the following, confirmed by a diagnostic pathology report:

• Recurrence within 1 year, low-grade Ta

• Solitary low-grade Ta >3 cm

• Low-grade Ta, multifocal

• High-grade Ta, ≤3 cm

• Low-grade T1

​​

​

​

​​

Bladder Cancer

A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA).​

​

​

​

​

To see if you qualify for one of the above trials, please send us an email.